Synthomer Valuation

Is SYNT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYNT (£1.64) is trading below our estimate of fair value (£3.02)

Significantly Below Fair Value: SYNT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNT?

Key metric: As SYNT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SYNT. This is calculated by dividing SYNT's market cap by their current revenue.
What is SYNT's PS Ratio?
PS Ratio0.1x
SalesUK£1.97b
Market CapUK£267.92m

Price to Sales Ratio vs Peers

How does SYNT's PS Ratio compare to its peers?

The above table shows the PS ratio for SYNT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
TET Treatt
1.8x7.2%UK£254.1m
ELM Elementis
1.4x3.4%UK£789.9m
VCT Victrex
2.6x5.8%UK£750.5m
JMAT Johnson Matthey
0.2x-43.3%UK£2.5b
SYNT Synthomer
0.1x5.0%UK£267.9m

Price-To-Sales vs Peers: SYNT is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (1.5x).


Price to Sales Ratio vs Industry

How does SYNT's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.1.2x-6.8%
SYNT Synthomer
0.1x5.0%US$337.46m
JMAT Johnson Matthey
0.2x-43.3%US$3.21b
CAR Carclo
0.2x7.0%US$29.96m
SYNT 0.1xIndustry Avg. 1.2xNo. of Companies6PS01.22.43.64.86+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.2x28.1%
SYNT Synthomer
0.1x81.3%US$337.46m
No more companies

Price-To-Sales vs Industry: SYNT is good value based on its Price-To-Sales Ratio (0.1x) compared to the UK Chemicals industry average (1.2x).


Price to Sales Ratio vs Fair Ratio

What is SYNT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: SYNT is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYNT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.64
UK£2.64
+61.2%
22.5%UK£4.10UK£2.00n/a10
Nov ’25UK£1.86
UK£2.67
+43.9%
23.2%UK£4.10UK£2.05n/a10
Oct ’25UK£2.15
UK£2.99
+39.4%
17.6%UK£4.10UK£2.30n/a10
Sep ’25UK£2.44
UK£3.00
+23.0%
18.0%UK£4.16UK£2.30n/a10
Aug ’25UK£2.58
UK£3.07
+19.3%
17.4%UK£4.16UK£2.50n/a10
Jul ’25UK£2.69
UK£3.05
+13.4%
19.7%UK£4.16UK£2.20n/a10
Jun ’25UK£2.90
UK£3.03
+4.5%
20.3%UK£4.16UK£2.20n/a10
May ’25UK£2.62
UK£2.75
+5.2%
26.5%UK£4.16UK£1.55n/a10
Apr ’25UK£2.60
UK£2.75
+5.9%
26.5%UK£4.16UK£1.55n/a10
Mar ’25UK£1.54
UK£7.63
+395.5%
146.2%UK£38.00UK£1.30n/a10
Feb ’25UK£1.45
UK£7.75
+435.3%
143.3%UK£38.00UK£1.30n/a10
Jan ’25UK£1.90
UK£19.94
+951.1%
81.3%UK£46.00UK£2.30n/a10
Dec ’24UK£1.83
UK£20.14
+1,003.6%
81.8%UK£46.00UK£2.30n/a10
Nov ’24UK£1.96
UK£23.37
+1,092.4%
53.6%UK£43.00UK£4.00UK£1.867
Oct ’24UK£2.32
UK£25.58
+1,002.4%
33.3%UK£40.00UK£16.00UK£2.158
Sep ’24UK£12.45
UK£25.69
+106.4%
39.4%UK£45.00UK£15.00UK£2.4411
Aug ’24UK£16.84
UK£27.72
+64.6%
36.5%UK£45.00UK£15.00UK£2.5812
Jul ’24UK£14.58
UK£32.78
+124.9%
21.4%UK£45.00UK£20.00UK£2.6912
Jun ’24UK£17.97
UK£33.22
+84.8%
22.4%UK£45.00UK£20.00UK£2.9012
May ’24UK£23.92
UK£32.66
+36.5%
22.9%UK£45.00UK£20.00UK£2.6213
Apr ’24UK£23.34
UK£38.76
+66.1%
42.9%UK£92.00UK£20.00UK£2.6014
Mar ’24UK£29.86
UK£39.58
+32.6%
42.5%UK£92.00UK£24.00UK£1.5413
Feb ’24UK£31.08
UK£38.77
+24.7%
43.9%UK£92.00UK£24.00UK£1.4513
Jan ’24UK£28.84
UK£42.00
+45.6%
51.5%UK£92.00UK£22.00UK£1.9013
Dec ’23UK£26.32
UK£44.79
+70.2%
46.5%UK£92.00UK£22.00UK£1.8314
Nov ’23UK£24.20
UK£47.83
+97.6%
46.6%UK£92.00UK£22.00UK£1.9614

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies